bullish
CSL/Vifor Pharma: Recommended Offer on Expanding Dialysis Market
241 Views21 Dec 2021 16:16
Deal is predicated on pipeline, future prospects for renal disease and iron deficiency. Adjusted gross spread is 2.8%. Long GALN SW (there's FX risk, which can be hedged).
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 5-minute read)
Discussions
(Paid Plans Only)
Top Quartile
Jesus Rodriguez Aguilar
European Event-Driven Analyst
Price Chart(Sign Up to Access)
- CSL/Vifor Pharma: Recommended Offer on Expanding Dialysis Market21 Dec 2021
x